
Quarterly Result30 Oct 2026, 01:00 pm
Ajanta Pharma Declares Q2 FY27 Unaudited Financial Results
AI Summary
Ajanta Pharma Ltd. announced its unaudited financial results for the second quarter and half year ended September 30, 2026. The company reported strong performance with consolidated revenue from operations at ₹1,794 crore for Q2 FY27, a 33% increase year-on-year. Profit after tax (PAT) also saw a significant rise of 49% to ₹388 crore. For the half year ended September 30, 2026, revenue grew by 29% to ₹3,420 crore, and PAT increased by 40% to ₹722 crore. The company also highlighted its performance in various market segments and its ANDA filings with the US FDA.
Key Highlights
- Board approved unaudited financial results for Q2 and H1 FY27.
- Consolidated revenue up 33% to ₹1,794 crore in Q2 FY27.
- Consolidated PAT up 49% to ₹388 crore in Q2 FY27.
- H1 FY27 revenue up 29% to ₹3,420 crore, PAT up 40% to ₹722 crore.
- Company provided updates on market performance and US FDA ANDA filings.
Price Impact
More from AJANTPHARM